Organs at risk in the brain and their dose-constraints in adults and in children: A radiation oncologist’s guide for delineation in everyday practice

2015 ◽  
Vol 114 (2) ◽  
pp. 230-238 ◽  
Author(s):  
Silvia Scoccianti ◽  
Beatrice Detti ◽  
Davide Gadda ◽  
Daniela Greto ◽  
Ilaria Furfaro ◽  
...  
2014 ◽  
Vol 16 (suppl 2) ◽  
pp. ii70-ii70
Author(s):  
S. Scoccianti ◽  
B. Detti ◽  
D. Greto ◽  
D. Gadda ◽  
I. F. Furfaro ◽  
...  

2018 ◽  
Vol 128 (1) ◽  
pp. 26-36 ◽  
Author(s):  
Maarten Lambrecht ◽  
Daniëlle B.P. Eekers ◽  
Claire Alapetite ◽  
Neil G. Burnet ◽  
Valentin Calugaru ◽  
...  

2021 ◽  
pp. 102161
Author(s):  
Robert Poel ◽  
Elias Rüfenacht ◽  
Evelyn Hermann ◽  
Stefan Scheib ◽  
Peter Manser ◽  
...  

2019 ◽  
Vol 16 (1) ◽  
pp. 272-279
Author(s):  
Ehab A Hegazy

Radiotherapy of Spinal cord and brain tumor requires High care due to considerable changes in the white matter of the brain, which consequently lead to a reduction of patient learning and mental skills. It is considered a very critical tumor due to high sensitivity of gross volume location and normal tissues surrounding it, including eye, heart, plate thyroid, and testis. XiO planning systems, TLD dosimeter found in Mansoura university oncology department, CMS XIO USA TPS were compared using electron and photon beams with different energies at a different site in target volume and organs at risk. We conclude that regular calibration of planning systems and direct measurement of the dose delivered to main target and organs at risk should be done to avoid the difference between XiO planning systems and direct measurement by TLd.


2020 ◽  
Author(s):  
Lien-Chun Lin ◽  
Guo-Liang Jiang ◽  
Nitin Ohri ◽  
Zheng Wang ◽  
Jiade Lu ◽  
...  

Abstract Objective: To identify a safe carbon ion radiotherapy (CIRT) regimen for patients with locally advanced pancreatic cancer (LAPC). Methods: We generated treatment plans for 13 consecutive, unselected patients who were treated for LAPC with CIRT at our center using three dose and fractionation schedules: 4.6 GyRBE x 12, 4.0 GyRBE x 14, and 3.0 GyRBE x 17. We tested the ability to meet published dose constraints for the duodenum, stomach, and small bowel as a function of dose schedule and distance between the tumor and organs at risk. Results: Using 4.6 GyRBE x 12 and 4.0 GyRBE x 14, critical (high-dose) constraints could only reliably be achieved when target volumes were not immediately adjacent to organs at risk. Critical constraints could be met in all cases using 3.0 GyRBE x 17. Low-dose constraints could not uniformly be achieved using any dose schedule. Conclusion: While selected patients with LAPC may be treated safely with a CIRT regimen of 4.6 GyRBE x 12, our dosimetric analyses indicate that a more conservative schedule of 3.0 GyRBE x 17 may be required to safely treat a broader population of LAPC patients, including those with large tumors and tumors that approach gastrointestinal organs at risk. The result of this work was used to guide an ongoing clinical trial.


2021 ◽  
Vol 161 ◽  
pp. S473-S475
Author(s):  
E.L. Lorenzen ◽  
J.F. Kallehauge ◽  
C.S. Byskov ◽  
R.H. Dahlrot ◽  
C.A. Haslund ◽  
...  

2020 ◽  
Author(s):  
Lien-Chun Lin ◽  
Guo-Liang Jiang ◽  
Nitin Ohri ◽  
Zheng Wang ◽  
Jiade Lu ◽  
...  

Abstract ObjectiveTo identify a safe carbon ion radiotherapy (CIRT) regimen for patients with locally advanced pancreatic cancer (LAPC).MethodsWe generated treatment plans for 13 consecutive, unselected patients who were treated for LAPC with CIRT at our center using three dose and fractionation schedules: 4.6 GyRBE x 12, 4.0 GyRBE x 14, and 3.0 GyRBE x 17. We tested the ability to meet published dose constraints for the duodenum, stomach, and small bowel as a function of dose schedule and distance between the tumor and organs at risk.ResultsUsing 4.6 GyRBE x 12 and 4.0 GyRBE x 14, critical (high-dose) constraints could only reliably be achieved when target volumes were not immediately adjacent to organs at risk. Critical constraints could be met in all cases using 3.0 GyRBE x 17. Low-dose constraints could not uniformly be achieved using any dose schedule.ConclusionWhile selected patients with LAPC may be treated safely with a CIRT regimen of 4.6 GyRBE x 12, our dosimetric analyses indicate that a more conservative schedule of 3.0 GyRBE x 17 may be required to safely treat a broader population of LAPC patients, including those with large tumors and tumors that approach gastrointestinal organs at risk. The result of this work was used to guide an ongoing clinical trial.


Sign in / Sign up

Export Citation Format

Share Document